| Pharmaceutical Information |
| Drug Name |
Eluxadoline |
| Drug ID |
BADD_D00761 |
| Description |
Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D.
Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. |
| Indications and Usage |
For the treatment of irritable bowel syndrome with diarrhea (IBS-D). |
| Marketing Status |
approved; investigational |
| ATC Code |
A07DA06 |
| DrugBank ID |
DB09272
|
| KEGG ID |
D10403
|
| MeSH ID |
C583636
|
| PubChem ID |
11250029
|
| TTD Drug ID |
D09ZXR
|
| NDC Product Code |
59651-330; 61874-100; 61874-075; 69766-020; 69037-0042 |
| UNII |
45TPJ4MBQ1
|
| Synonyms |
eluxadoline | Viberzi |
|
| Chemical Information |
| Molecular Formula |
C32H35N5O5 |
| CAS Registry Number |
864821-90-9 |
| SMILES |
CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)
C(=O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
